OligoG and nystatin for candida biofilms: a promising lab finding, honestly framed
In 2023, a laboratory study reported that combining a seaweed-derived compound called OligoG with the antifungal nystatin reduced the amount of nystatin needed to inhibit Candida by up to 32-fold - a striking figure that has since travelled around gut-health circles as evidence that OligoG “cracks” candida biofilms. The finding is real and genuinely interesting. But the headline number is also widely misunderstood: it came from a single outlier strain in a test-tube assay, most strains barely responded, and there is not a single human trial of OligoG for candida or any gut condition. This note lays out exactly what was found, and what it does and doesn’t mean.
The short version
- The study is in-vitro only - cells in a dish, not people.1
- “Up to 32-fold” was one strain. Most of the thirteen Candida strains tested showed a 2-4-fold change or none at all.1
- OligoG is investigational. Its only clinical development is in cystic fibrosis; it is not a licensed antifungal or gut treatment.5
- No human candida or gut data exist. Treat this as a promising mechanism, not a therapy.
In this note
Why candida biofilms are the problem
Free-floating yeast cells are relatively easy to kill. The trouble is that Candida rarely stays free-floating. It builds a biofilm - a community of cells wrapped in a self-made matrix of sugars, proteins and DNA that physically shields the organisms and pumps drugs back out. Inside a mature biofilm, Candida can be far less susceptible to antifungals than the same species growing loose, and a subpopulation of dormant “persister” cells survives almost anything.3
That resistance is why device-related and recurrent candida infections are so stubborn, and it is the specific problem any “biofilm disruptor” is trying to solve: not to kill the yeast directly, but to break open the matrix so a conventional antifungal can do its job at a sensible dose.
What OligoG actually is
OligoG CF-5/20 is a low-molecular-weight alginate oligosaccharide - a short chain of sugars purified from marine brown seaweed - developed by the Norwegian company AlgiPharma. Its primary claim to interest is that it can chelate (bind) calcium and disrupt the biofilm matrix, which is why almost all of its real clinical development has been in cystic fibrosis, where thick, biofilm-laden mucus is the central problem. There, an inhaled powder form has been through phase 2 trials.4
The critical point for anyone reading about gut candida: OligoG is an investigational drug. It is not a licensed antifungal, not a licensed gut treatment, and not the same thing as the dietary alginate supplements sometimes marketed alongside it. Its development status is cystic-fibrosis-respiratory, not gastrointestinal.5
The 2023 study, in detail
The paper is Powell and colleagues, published in Frontiers in Cellular and Infection Microbiology, working with AlgiPharma.1 They tested OligoG combined with nystatin against thirteen Candida strains across several species, using broth assays, biofilm models on glass and silicone, electron microscopy, and membrane-permeability tests.
Here is what the “up to 32-fold” figure really is. In a test of free-floating (planktonic) yeast, one strain - Candida dubliniensis 40/01 - needed 32 times less nystatin to be inhibited when OligoG was added. That is the source of the headline. But the same paper is explicit that this was the standout: a couple of strains showed a roughly 4-fold improvement, and the remaining ten showed either a minimal 2-fold change or none at all.1 A single dramatic responder among thirteen is a reason to investigate further, not a general property you can count on.
| Finding | How it was measured | Result |
|---|---|---|
| “Up to 32-fold” potentiation | Free-floating (planktonic) MIC, one strain (C. dubliniensis) | ~32× less nystatin needed |
| The other twelve strains | Free-floating (planktonic) MIC | ~2-4× less, or no change |
| Effect on biofilms | Microscopy + cell-viability assays | Less biofilm, more dead cells - not a 32× dose drop |
| Human / clinical benefit | - | None - no trials exist |
The biofilm point is subtler than the headline. The “32-fold” came from free-floating yeast, not from a biofilm measurement. Against actual biofilms, OligoG plus nystatin did show benefit - less biofilm formation and more dead cells on imaging - but that was demonstrated through microscopy and viability assays, not a 32-fold drop in required dose. Conflating the two overstates the result.
The proposed mechanism is consistent and plausible: combined treatment appeared to disorganise the Candida cell membrane and make it more permeable, which would let more nystatin in. This echoes an earlier 2014 study that first reported alginate oligosaccharides potentiating antifungals, with more modest figures (around 16-fold for nystatin in that work).2 So there is a small, coherent body of laboratory evidence here - just not clinical evidence.
Why nystatin is a logical partner
If you were going to pair a biofilm disruptor with an antifungal for a gut problem, nystatin is an intuitive choice. It is barely absorbed from the intestine, so it concentrates in the gut lumen and acts locally with minimal systemic exposure.6 In principle, a matrix-opening agent that let nystatin reach yeast it otherwise couldn’t penetrate is an elegant idea. The logic is sound; it is the human evidence that is missing. Nystatin itself is covered in the nystatin for gut candida guide, and the wider context in the candida overgrowth pillar.
The limitations that matter
Four things should temper any enthusiasm:
- It is in-vitro. Effects in a dish frequently fail to translate to the living gut, where mucus, food, transit and the wider microbiome all interfere.
- The dramatic figure is one strain. Generalising “32-fold” to Candida as a whole is not supported by the paper’s own data.
- It is industry-linked. The study was funded by, and co-authored with, the company developing OligoG - reason for ordinary caution, not dismissal.
- There is no gut or candida clinical evidence at all. Not a single human trial of OligoG for candida, SIFO, or any intestinal condition. The only human data are respiratory, in cystic fibrosis.
What this means in practice: OligoG is not something to source and self-administer for gut candida. It is an investigational compound being studied for a different organ, and pairing it with an off-label antifungal outside a trial would be experimenting on yourself. Interesting science is not the same as a treatment you can use.
UK and regulatory status
OligoG holds orphan drug designation for cystic fibrosis and remains in clinical development for that indication.5 It has no marketing authorisation for candida, for gut conditions, or indeed for anything - orphan designation is an incentive for research, not an approval. In the UK there is no licensed OligoG product you could be prescribed for a gut problem.
Questions for a clinician
If a practitioner proposes OligoG for your gut
- What human evidence exists for OligoG in gut candida specifically - as opposed to laboratory or cystic fibrosis data?
- Is the product you’re suggesting actually OligoG CF-5/20, and is it licensed or regulated for this use?
- What are we hoping it adds beyond a standard, supervised antifungal approach?
- How would we know if it was helping or harming, and what is the exit plan if it isn’t?
References
- Powell LC, Adams JYM, et al. Alginate oligosaccharides enhance the antifungal activity of nystatin against candidal biofilms. Front Cell Infect Microbiol. 10.3389/fcimb.2023.1122340, 2023.
- Tøndervik A, et al. Alginate oligosaccharides inhibit fungal cell growth and potentiate the activity of antifungals. PLOS ONE. 10.1371/journal.pone.0112518, 2014.
- Taff HT, et al. Mechanisms of Candida biofilm drug resistance. Future Microbiol. PMC3859465, 2013.
- Van Koningsbruggen-Rietschel S, et al. Inhaled OligoG CF-5/20 in cystic fibrosis: a phase 2b trial. ERJ Open Res. PMC7569163, 2020.
- AlgiPharma. OligoG clinical trials and development status (orphan drug designation, cystic fibrosis). algipharma.com.
- Nystatin oral suspension, Summary of Product Characteristics (not absorbed from the GI tract). medicines.org.uk (emc), 2023.
- Pritchard MF, et al. OligoG modifies Candida albicans hyphal infiltration in an in-vitro model. J Appl Microbiol. PMID 28635170, 2017.
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.